SMS Pharmaceuticals Ltd (SMSPHARMA) is currently trading at 514.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

SMS Pharmaceuticals Limited is an India-headquartered Active Pharmaceutical Ingredient (API) manufacturer and developer, founded in 1987, operating multiple accredited manufacturing sites and an R&D centre, supplying regulated markets with niche and high-value APIs across 14 therapeutic areas. Q1FY27 revenue was ₹206.96 crore, up 6% year-on-year, with gross margin improving to 36% and EBITDA margin sustained at about 20%, reflecting structural margin improvement from higher share of high-value products and operational leverage. The company is pursuing an aggressive capex and product filing cadence: a ₹280 crore capex programme expected complete by FY27, planned doubling of near-term R&D spend, and a target of 20 DMF/CEP/dossier filings over the next 24 months to commercialise new molecules. Operational strengths include six USFDA approvals across facilities, 120+ DMFs filed historically, a 3,120 KL reactor footprint for niche molecules plus 3,000 KL large-volume capacity, and a JV with Chemo Iberica that has already commercialised ibuprofen production to drive growth.

Over the past 52 weeks, SMS Pharmaceuticals Ltd has traded between a low of ₹270.80 and a high of ₹524.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

SMS Pharmaceuticals Ltd has a market capitalization of approximately 4,722.40. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

SMS Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 52.78 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,722.40 Cr, SMS Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

SMS Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of SMS Pharmaceuticals Ltd is 52.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone revenue was Rs 207.0 crore and standalone net profit was Rs 21.1 crore for Q1 FY27 (ended June 30, 2026).